ArticleHypertension research : official journal of the Japanese Society of Hypertension2025
Comparative analysis of plasma BNP and NT-proBNP levels, and NT-proBNP/BNP ratio in patients with chronic kidney disease.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Natriuretic Peptides as Predictors for the Diagnosis of Pulmonary Hypertension Secondary to Left Heart Disease and for the Assessment of Its Severity.International journal of molecular sciences · 2026Article
- Management Strategies for Congestive Heart Failure in Chronic Kidney Disease: Narrative Review.Biomedicines · 2026Review
- Comment on "Comparative analysis of plasma BNP and NT-proBNP levels, and NT-proBNP/BNP ratio in patients with chronic kidney disease".Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Early neurological rehabilitation management in a stroke patient with persistently and extremely elevated natriuretic peptides: a case report.Frontiers in medicine · 2026Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are clinically used for diagnosing and monitoring heart failure. However, their levels are influenced by several factors, and their impacts on chronic kidney disease (CKD) patients remain unclear. This study included 1036 patients who visited the Nephrology division at our hospital between 2014 and 2015. Plasma BNP, NT-proBNP levels and the BNP/NT-proBNP ratio were measured at each CKD stage, and their correlation with clinical factors were analyzed. This study included 1037 patients with stage 1 to stage 5D CKD (CKD 1-2, n = 114; CKD 3, n = 256; CKD 4, n = 266; CKD 5, n = 298; CKD 5D, n = 102). Levels of plasma BNP and NT-proBNP levels and the NT-proBNP/BNP ratio increased, and the correlation between BNP and NT-proBNP levels weakened with declining kidney function. Although various clinical factors were found to be significantly correlated with these parameters, multivariate analysis showed that male gender and hemoglobin, phosphate, and parathyroid hormone levels were significantly correlated with both plasma BNP and NT-proBNP levels. Notably, a higher NT-proBNP/BNP ratio was significantly associated with increased cardiovascular events in patients with CKD stages 4 and 5. As plasma BNP and NT-proBNP levels are influenced by various factors in patients with CKD, careful interpretation of these parameters is essential. In patients with advanced-stage CKD, the NT-proBNP/BNP ratio may be a useful predictor of CVD development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.